


**Amendments to the Claims:**

The listing of the claims provided below will replace all prior versions and listings of claims in the application.

**Listing of the Claims:**

1. (Currently Amended)      Pharmaceutical formulation, comprising containing  
a xanthogenate of formula I



(I)

wherein R<sub>1</sub> represents an optionally substituted aryl or alkyl residue, and R<sub>2</sub> represents a metal atom, an optionally substituted alkyl, alkoxy, amino or ammonium group or halogen, and

an inhibitor of viral nucleic acid replication, and  
optionally an adjuvant enhancing the activity of the xanthogenate, and  
optionally a carrier substance reducing the irritating effect.

2. (Currently Amended)      Pharmaceutical formulation according to claim 1, wherein  
~~characterized in that~~ R<sub>1</sub> is an adamantyl, norbornyl, tricyclodecyl, benzyl, linear or branched C<sub>3</sub>-C<sub>20</sub> alkyl, C<sub>3</sub>-C<sub>20</sub> cycloalkyl, furyl, pyridyl, anthracyl, naphthyl, phenanthryl, perinaphthyl or quinuclidinyl residue, whereby the said aforementioned linear or branched C<sub>3</sub>-C<sub>20</sub> alkyl residue can be substituted by a hydroxyl, a C<sub>1</sub>-C<sub>4</sub> alkoxy group, a halogen atom or an amino group, and the said aforementioned C<sub>3</sub>-C<sub>20</sub> cycloalkyl residue can also be substituted by a hydroxyl, a C<sub>1</sub>-C<sub>4</sub> alkoxy, ~~or~~ a C<sub>1</sub>-C<sub>4</sub> alkyl group, a halogen atom or an amino group.
3. (Currently Amended)      Pharmaceutical formulation according to claim 2, wherein  
~~characterized in that~~ R<sub>1</sub> is a cyclododecyl, dodecyl, undecyl, decyl, tricyclo[5,2,1,0<sup>2,6</sup>]-decyl, nonyl, octyl, bicyclo[2,2,1]-heptyl, cyclohexyl, hexyl or toluyl residue.

4. (Currently Amended)      Pharmaceutical formulation according to claim 1, wherein any one of the claims 1 to 3, characterized in that R<sub>2</sub> is a sodium or potassium atom or a dimethylglycylester or methylester group.
5. (Currently Amended)      Pharmaceutical formulation according to claim 1, wherein any one of the claims 1 to 4, characterized in that the inhibitor of viral nucleic acid replication is a nucleoside analogue.
6. (Currently Amended)      Pharmaceutical formulation according to claim 5, wherein characterized in that the inhibitor of viral nucleic acid replication is selected from aciclovir, valaciclovir, penciclovir, and famciclovir.
7. (Currently Amended)      Pharmaceutical formulation according to claim 1, comprising any one of the preceding claims, characterized in that it contains 1 to 10, preferably 2 to 4 parts inhibitor of viral nucleic acid replication per one part xanthogenate.
8. (Currently Amended)      Pharmaceutical formulation according to claim 1, comprising any one of the claims 1 to 7, characterized in that it contains an ionic detergent as adjuvant, preferably a fatty acid with 6 to 19 C atoms or an alkylsulphate with 8 to 18 C atoms.
9. (Currently Amended)      Pharmaceutical formulation according to claim 1, comprising any one of the claims 1 to 7, characterized in that it contains deoxycholic acid or a pharmaceutically tolerable salt thereof as adjuvant.
10. (Currently Amended)      Pharmaceutical formulation according to claim 1, comprising any one of the claims 1 to 7, characterized in that it contains a phosphonic acid as adjuvant.
11. (Currently Amended)      Pharmaceutical formulation according to claim 1, comprising claims 1 to 10, characterized in that it contains, in addition, cholesterol as carrier substance.
12. (Cancelled)

13. (Currently Amended) Pharmaceutical formulation Agent according to claim 1, wherein ~~the xanthogenate is 12, characterized in that it contains~~ tricyclo[5,2,1,0<sup>2,6</sup>]-decane-9-yl-xanthogenate ~~as xanthogenate, the carrier substance is~~ cholesterol or phosphatidylcholine ~~as carrier substance, the adjuvant is~~ the sodium or potassium salt of decanoic acid ~~as adjuvant~~, and the inhibitor of viral nucleic acid replication is selected from aciclovir, valaciclovir, penciclovir, and famciclovir.

14. (Currently Amended) Pharmaceutical formulation Agent according to claim 13, ~~wherein the~~ ~~characterized in that it contains~~ aciclovir ~~as inhibitor of viral nucleic acid replication~~ is aciclovir.

15. (Currently Amended) Pharmaceutical formulation Agent according to claim 1, ~~comprising at least one of the claims 12 to 14, characterized in that it contains~~ one part xanthogenate, one part inhibitor of viral nucleic acid replication, four parts carrier substance, and one part adjuvant.


16. (Currently Amended) Pharmaceutical formulation Agent according to claim 1, further ~~comprising at least one of the claims 12 to 14, characterized in that it is an ointment that contains the pharmaceutical formulation in a lipophilic substance as excipient for administration as an ointment, preferably vaseline.~~

17. (New) Pharmaceutical formulation according to claim 16, wherein the lipophilic substance is vasoline.

18. (New) Pharmaceutical formulation according to claim 7, comprising 2 to 4 parts inhibitor of viral nucleic acid replication per one part xanthogenate.

19. (New) Pharmaceutical formulation according to claim 8, wherein the ionic detergent is a fatty acid with 6 to 19 C atoms or an alkylsulphate with 8 to 18 C atoms.

20. (New) Method for the treatment of viral, tumor, or autoimmune diseases comprising administering to a patient in need thereof an effective amount of a xanthogenate of formula I



wherein  $\text{R}_1$  represents an optionally substituted aryl or alkyl residue, and  $\text{R}_2$  represents a metal atom, an optionally substituted alkyl, alkoxy, amino or ammonium group or halogen, and an effective amount of an inhibitor of viral nucleic acid replication.

21. (New) Method according to claim 20, **wherein**  $\text{R}_1$  is a cyclododecyl, dodecyl, undecyl, decyl, tricyclo[5,2,1,0<sup>2,6</sup>]-decyl, nonyl, octyl, bicyclo[2,2,1]-heptyl, cyclohexyl, hexyl or toluyl residue and  $\text{R}_2$  is a sodium or potassium atom or a dimethyl-glycylester or methylester group.

22. (New) Method according to claim 20, **wherein** the inhibitor of viral nucleic acid replication is selected from aciclovir, valaciclovir, penciclovir, and famciclovir.

23. (New) Method according to claim 20, further comprising cholesterol or phosphatidylcholine as a carrier substance, and sodium or potassium salt of decanoic acid as an adjuvant, and **wherein** the xanthogenate is tricyclo[5,2,1,0<sup>2,6</sup>]-decane-9-yl-xanthogenate, and the inhibitor of viral nucleic acid replication is selected from aciclovir, valaciclovir, penciclovir, and famciclovir.